Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 17 | 2026 | 1129 | 4.160 |
Why?
|
| Acute-On-Chronic Liver Failure | 3 | 2023 | 73 | 1.870 |
Why?
|
| Adenovirus Infections, Human | 3 | 2026 | 61 | 1.820 |
Why?
|
| Biliary Atresia | 3 | 2023 | 223 | 1.650 |
Why?
|
| Liver Failure, Acute | 5 | 2026 | 95 | 1.350 |
Why?
|
| Gastroenterology | 2 | 2024 | 223 | 1.300 |
Why?
|
| Adenoviridae Infections | 1 | 2026 | 77 | 0.910 |
Why?
|
| Pediatrics | 2 | 2024 | 1242 | 0.820 |
Why?
|
| Fellowships and Scholarships | 2 | 2024 | 323 | 0.810 |
Why?
|
| Postoperative Complications | 4 | 2026 | 3115 | 0.770 |
Why?
|
| Varicose Veins | 1 | 2022 | 27 | 0.750 |
Why?
|
| Hepatorenal Syndrome | 1 | 2022 | 31 | 0.740 |
Why?
|
| Registries | 4 | 2025 | 1614 | 0.730 |
Why?
|
| Liver Cirrhosis | 4 | 2022 | 899 | 0.730 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2022 | 72 | 0.720 |
Why?
|
| End Stage Liver Disease | 2 | 2025 | 192 | 0.720 |
Why?
|
| Hypertension, Portal | 1 | 2022 | 78 | 0.710 |
Why?
|
| Education, Medical, Graduate | 2 | 2024 | 551 | 0.700 |
Why?
|
| Curriculum | 2 | 2024 | 792 | 0.700 |
Why?
|
| Hepatic Artery | 3 | 2022 | 45 | 0.700 |
Why?
|
| Respiratory Insufficiency | 2 | 2022 | 244 | 0.680 |
Why?
|
| Gastroenteritis | 1 | 2023 | 308 | 0.640 |
Why?
|
| Bradycardia | 1 | 2020 | 57 | 0.640 |
Why?
|
| Dexmedetomidine | 1 | 2020 | 47 | 0.630 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 131 | 0.600 |
Why?
|
| Thrombosis | 3 | 2022 | 500 | 0.590 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 157 | 0.580 |
Why?
|
| Patient Admission | 1 | 2020 | 186 | 0.580 |
Why?
|
| Infant | 15 | 2026 | 13270 | 0.530 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2017 | 14 | 0.520 |
Why?
|
| Liver | 3 | 2026 | 1789 | 0.510 |
Why?
|
| Child | 17 | 2026 | 26175 | 0.500 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 401 | 0.480 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 227 | 0.460 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 228 | 0.440 |
Why?
|
| Retrospective Studies | 13 | 2026 | 17558 | 0.410 |
Why?
|
| Liver Failure | 2 | 2026 | 99 | 0.380 |
Why?
|
| Child, Preschool | 10 | 2026 | 14989 | 0.370 |
Why?
|
| Adenoviruses, Human | 2 | 2023 | 97 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 774 | 0.330 |
Why?
|
| Humans | 24 | 2026 | 130556 | 0.310 |
Why?
|
| Heart Defects, Congenital | 1 | 2020 | 1876 | 0.280 |
Why?
|
| Perforin | 1 | 2026 | 24 | 0.240 |
Why?
|
| Infant, Newborn | 5 | 2025 | 8545 | 0.240 |
Why?
|
| Hospitalization | 4 | 2025 | 1939 | 0.230 |
Why?
|
| Male | 12 | 2026 | 64536 | 0.230 |
Why?
|
| Thrombelastography | 1 | 2026 | 69 | 0.220 |
Why?
|
| International Normalized Ratio | 2 | 2026 | 45 | 0.220 |
Why?
|
| Blood Loss, Surgical | 1 | 2026 | 168 | 0.210 |
Why?
|
| Waiting Lists | 2 | 2025 | 245 | 0.210 |
Why?
|
| Female | 10 | 2026 | 70427 | 0.210 |
Why?
|
| Immunocompromised Host | 1 | 2026 | 310 | 0.200 |
Why?
|
| Interferon-gamma | 1 | 2026 | 550 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2025 | 225 | 0.190 |
Why?
|
| Adolescent | 7 | 2026 | 20774 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2026 | 463 | 0.190 |
Why?
|
| Cholestasis | 1 | 2025 | 170 | 0.190 |
Why?
|
| Peritonitis | 1 | 2022 | 75 | 0.190 |
Why?
|
| Canada | 1 | 2023 | 325 | 0.180 |
Why?
|
| Ascites | 1 | 2022 | 99 | 0.180 |
Why?
|
| Hepatitis | 1 | 2022 | 56 | 0.180 |
Why?
|
| Bacterial Infections | 1 | 2025 | 328 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2025 | 406 | 0.170 |
Why?
|
| Hemochromatosis | 1 | 2021 | 39 | 0.170 |
Why?
|
| Antithrombins | 1 | 2021 | 49 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2025 | 789 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 164 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2026 | 801 | 0.160 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 80 | 0.160 |
Why?
|
| Adenoviridae | 1 | 2023 | 582 | 0.160 |
Why?
|
| Forecasting | 1 | 2021 | 350 | 0.150 |
Why?
|
| Prevalence | 1 | 2026 | 2688 | 0.140 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 145 | 0.140 |
Why?
|
| Length of Stay | 2 | 2025 | 1404 | 0.140 |
Why?
|
| Creatinine | 1 | 2020 | 396 | 0.140 |
Why?
|
| Incidence | 1 | 2026 | 3320 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2022 | 378 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2021 | 688 | 0.130 |
Why?
|
| Philadelphia | 1 | 2017 | 29 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2024 | 1060 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2025 | 971 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12866 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2020 | 526 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 62 | 0.120 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2016 | 24 | 0.120 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2016 | 56 | 0.120 |
Why?
|
| Anticoagulants | 2 | 2022 | 602 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2016 | 191 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1060 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2025 | 1362 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2016 | 216 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 215 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 4034 | 0.100 |
Why?
|
| Recurrence | 1 | 2017 | 1478 | 0.100 |
Why?
|
| Risk Factors | 3 | 2025 | 10967 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2017 | 800 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 4867 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2326 | 0.070 |
Why?
|
| United States | 1 | 2023 | 11882 | 0.070 |
Why?
|
| Yttrium Radioisotopes | 1 | 2025 | 23 | 0.060 |
Why?
|
| Blood Coagulation Tests | 1 | 2026 | 65 | 0.060 |
Why?
|
| Partial Thromboplastin Time | 1 | 2026 | 55 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2026 | 134 | 0.060 |
Why?
|
| Fibrinogen | 1 | 2026 | 170 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2025 | 222 | 0.050 |
Why?
|
| ROC Curve | 1 | 2026 | 611 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2026 | 634 | 0.050 |
Why?
|
| Young Adult | 1 | 2017 | 10015 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2024 | 165 | 0.050 |
Why?
|
| Portal Vein | 1 | 2022 | 84 | 0.040 |
Why?
|
| Catheters | 1 | 2022 | 81 | 0.040 |
Why?
|
| Viremia | 1 | 2022 | 130 | 0.040 |
Why?
|
| Hirudins | 1 | 2021 | 39 | 0.040 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2021 | 42 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 459 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2294 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 1154 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1317 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2830 | 0.030 |
Why?
|
| Adult | 1 | 2024 | 31157 | 0.010 |
Why?
|